CO2021014694A2 - Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio - Google Patents

Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio

Info

Publication number
CO2021014694A2
CO2021014694A2 CONC2021/0014694A CO2021014694A CO2021014694A2 CO 2021014694 A2 CO2021014694 A2 CO 2021014694A2 CO 2021014694 A CO2021014694 A CO 2021014694A CO 2021014694 A2 CO2021014694 A2 CO 2021014694A2
Authority
CO
Colombia
Prior art keywords
prevention
treatment
respiratory tract
tract infection
subunit vaccine
Prior art date
Application number
CONC2021/0014694A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Meinke
Fabien Perugi
Klaus Schwamborn
Wolfgang Schüler
Urban Lundberg
Original Assignee
Valneva Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Se filed Critical Valneva Se
Publication of CO2021014694A2 publication Critical patent/CO2021014694A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2021/0014694A 2019-05-20 2021-10-29 Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio CO2021014694A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (1)

Publication Number Publication Date
CO2021014694A2 true CO2021014694A2 (es) 2022-01-17

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014694A CO2021014694A2 (es) 2019-05-20 2021-10-29 Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio

Country Status (21)

Country Link
US (3) US12162907B2 (enExample)
EP (1) EP3972639A1 (enExample)
JP (1) JP2022533318A (enExample)
KR (1) KR20220010478A (enExample)
CN (1) CN114127101A (enExample)
AU (1) AU2020277661A1 (enExample)
BR (1) BR112021021637A2 (enExample)
CA (1) CA3138064A1 (enExample)
CL (1) CL2021002819A1 (enExample)
CO (1) CO2021014694A2 (enExample)
EC (1) ECSP21079178A (enExample)
GB (1) GB2598494B (enExample)
IL (1) IL287099A (enExample)
MX (1) MX2021013111A (enExample)
MY (1) MY208001A (enExample)
PE (1) PE20220400A1 (enExample)
PH (1) PH12021552736A1 (enExample)
SA (1) SA521430813B1 (enExample)
SG (1) SG11202110646PA (enExample)
WO (1) WO2020234300A1 (enExample)
ZA (1) ZA202106883B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
IL297166A (en) 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
IL320367A (en) 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins
KR20230107621A (ko) 2020-11-13 2023-07-17 아이코사백스, 인크. 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
KR20230167017A (ko) * 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신
US20240335523A1 (en) * 2021-08-05 2024-10-10 The Regents Of The University Of California Glycoengineered Foldon Domains and Related Compositions and Methods
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
CN121263205A (zh) * 2023-02-06 2026-01-02 塞维卡有限责任公司 修饰的piv5疫苗载体：制造方法和用途
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
CN119176858B (zh) * 2024-11-22 2026-01-09 北京华诺泰生物医药科技有限公司 一种重组人偏肺病毒融合前f蛋白纯化方法
CN122011136A (zh) * 2026-04-13 2026-05-12 北京民海生物科技有限公司 一种融合前人偏肺病毒f蛋白的突变体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
EP1390494A2 (en) 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
US20050250716A1 (en) 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
CN101410519B (zh) * 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
EP4400115A3 (en) 2011-12-06 2024-10-23 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
CN105408348B (zh) * 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
US10420834B2 (en) * 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신

Also Published As

Publication number Publication date
SA521430813B1 (ar) 2024-04-27
KR20220010478A (ko) 2022-01-25
US20240067681A1 (en) 2024-02-29
GB202114836D0 (en) 2021-12-01
GB2598494A (en) 2022-03-02
BR112021021637A2 (pt) 2021-12-21
EP3972639A1 (en) 2022-03-30
US20220185847A1 (en) 2022-06-16
GB2598494B (en) 2024-07-24
WO2020234300A1 (en) 2020-11-26
PE20220400A1 (es) 2022-03-22
IL287099A (en) 2021-12-01
MY208001A (en) 2025-04-03
AU2020277661A1 (en) 2021-10-21
CA3138064A1 (en) 2020-11-26
MX2021013111A (es) 2021-11-17
CL2021002819A1 (es) 2022-07-08
ZA202106883B (en) 2022-07-27
JP2022533318A (ja) 2022-07-22
ECSP21079178A (es) 2021-11-30
US12162909B2 (en) 2024-12-10
US12162907B2 (en) 2024-12-10
CN114127101A (zh) 2022-03-01
PH12021552736A1 (en) 2022-07-11
SG11202110646PA (en) 2021-10-28
US20250171501A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
CL2021002819A1 (es) Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
MX364942B (es) Peptidos antimicrobianos.
CU24117B1 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
MX2015012397A (es) Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
BR112015031509A2 (pt) Polipeptídeo, molécula de ácido nucleico, vetor, e, composição
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
MX391440B (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2017000714A1 (es) Composiciones farmacéuticas de acción prolongada
MX2017002385A (es) Metodos y reactivos para la prevencion y/o el tratamiento de infecciones.
MX2017009094A (es) Derivado de polimixina y usos del mismo.
CO2020008887A2 (es) Inhibidores de pi4kiiiβ